According to the latest report by IMARC Group, titled “Sleep Apnea Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global sleep apnea devices market size reached US$ 7.5 Billion in 2022. Sleep apnea, or sleep-disordered breathing (SDB), is a chronic sleeping disorder in which breathing repeatedly starts and stops. It is caused by a blockage in the airway, which reduces the airflow, resulting in irregular breathing patterns and loud snoring. Sleep apnea can be treated through therapeutic and diagnostic machines. Some of these devices include positive airway pressure (PAP), continuous positive airway pressure (CPAP), variable positive airway pressure (VPAP), and bilevel positive airway pressure (BiPAP) machines and chin straps. These machines enable the optimum supply of oxygen and help improve sleep quality, maintain heart health, and prevent various health issues. In addition to this, oral equipment, such as MAD and tongue-retaining devices, are also utilized to treat mild to moderate cases of sleep apnea.
Global Sleep Apnea Devices Market Trends:
The widespread prevalence of obstructive sleep apnea (OSA) and central and complex sleep apnea syndrome, especially among the geriatric population and individuals with diabetes, hypertension, and cardiovascular diseases (CVDs), is the primary factor fueling the global sleep apnea market growth. Besides this, the escalating awareness about the detrimental health effects of undiagnosed sleep apnea is acting as another significant growth-inducing factor. Moreover, the rising adoption of telemedicine platforms, sleep ventilators, and artificial intelligence (AI)-enabled home sleep apnea tests (HSATs) and PAP devices is contributing to the market growth. In addition to this, ongoing product innovations, increasing miniaturization, and the advent of out-of-center (OOC) testing devices that examine sleep patterns and cardiovascular, oximetry, and respiratory parameters for diagnosing OSA are presenting remunerative growth opportunities for the market. In line with this, the launch of mandibular advancement devices (MADs) as an alternative to CPAP, and the surging uptake in cost-effective and portable non-invasive diagnostic devices for treatment purposes, are aiding in market expansion. Furthermore, significant advancements in the healthcare infrastructure and favorable reimbursements and financial support by governments for sleep apnea devices are creating a positive outlook for the market. Looking forward, the market value is projected to reach US$ 11.2 Billion by 2028, expanding at a CAGR of 6.8 % during 2023-2028.
- Based on the product type, the market is bifurcated into therapeutic devices (positive airway pressure (PAP) devices, oral devices, nasal devices, chin straps, and others) and diagnostic devices (actigraphs, polysomnography, sleep screening, and others). Between these, therapeutic devices dominate the market.
- On the basis of the end-user, the market has been segregated into hospitals and clinics, sleep laboratories, homecare settings, and others. Among these, homecare settings accounts for the largest market share.
- On a regional basis, the market has been segmented into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Latin America (Brazil, Mexico, Argentina, Colombia, Chile, Peru, and others), and Middle East and Africa (Turkey, Saudi Arabia, Iran, Unite Arab Emirates, and others). Currently, North America represents the largest market for sleep apnea devices.
- The competitive landscape of the market has also been examined, with some of the key players being BMC Medical Co., Braebon Medical Corporation, Cadwell Laboratories, CareFusion Corp., Curative Medical, Devilbiss Healthcare, Fisher & Paykel Healthcare, GE Healthcare, Invacare, Oventus Medical, Panthera Dental, ResMed, Somnomed Ltd., Vyaire Medical Inc., Whole You Inc., etc.
|Base Year of the Analysis
||Product Type, End-User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico, Argentina, Colombia, Chile, Peru, Turkey, Saudi Arabia, Iran, United Arab Emirates
||BMC Medical Co., Braebon Medical Corporation, Cadwell Laboratories, CareFusion Corp., Curative Medical, Devilbiss Healthcare, Fisher & Paykel Healthcare, GE Healthcare, Invacare, Oventus Medical, Panthera Dental, ResMed, Somnomed Ltd., Vyaire Medical Inc. and Whole You Inc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800